Top 20 Cardiac Stent Manufacturers in Global

Cardiac stents are medical devices used to open and support narrowed or blocked coronary arteries in patients suffering from coronary artery disease (CAD). The stent, typically a mesh-like tube, is inserted into the artery to restore blood flow. With the global rise in heart disease, the demand for stents continues to grow. Several companies dominate the cardiac stent market by offering innovative solutions and leading-edge technologies.

This article lists the top 20 cardiac stent manufacturers in global, based on their market share, technological innovations, and contributions to the field of interventional cardiology.

Cardiac Stent Market Size and Growth

The global cardiac stent manufacturing market is a critical segment of the medical device industry, driven by advancements in technology, growing prevalence of cardiovascular diseases, and an increasing aging population. Cardiac stents are crucial in the treatment of coronary artery disease (CAD) by providing mechanical support to keep arteries open and facilitating blood flow to the heart.

As of 2024, the global cardiac stent market is valued at approximately USD 8.5 billion. This market is projected to grow at a compound annual growth rate (CAGR) of 6-8% over the next five years. The growth is fueled by several factors including technological advancements, increasing prevalence of heart diseases, and rising awareness of cardiovascular health.

The global cardiac stent manufacturing market is poised for steady growth driven by technological innovations, increasing prevalence of cardiovascular diseases, and expanding healthcare access. The market dynamics are influenced by a mix of advanced product offerings, evolving patient needs, and regional variations. As the industry evolves, continued investment in research and development will be crucial in addressing emerging challenges and leveraging new opportunities for growth.

Top 20 Cardiac Stent Manufacturers List

We will list 20 very famous Cardiac Stent Manufacturers below, in no particular order or size, just to provide a convenient suggestion.

Quality is more important than quantity, but without quantity there can be no quality.

Abbott Laboratories

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Green Oaks, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.[3][4]

Abbott’s products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip.Key Cardiac Stent Products:

• Xience Stent Series: Abbott’s flagship stent series, Xience, is known for its drug-eluting stents (DES). It uses Everolimus, an immunosuppressant drug, to prevent restenosis (the re-narrowing of the artery).
• Absorb Bioresorbable Stent: Although pulled from some markets, Abbott’s Absorb stent was a pioneering bioresorbable stent, designed to dissolve after providing temporary scaffolding.

In 2024, Abbott continues to lead the market with its Xience stent, which remains a gold standard for DES. Recent clinical trials highlight its long-term safety and efficacy.

Medtronic

Medtronic plc is an American-Irish medical device company. The company’s operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015.[3][4] While it primarily operates in the United States,[5][6] it operates in more than 150 countries and employs over 90,000 people.[7] It develops and manufactures healthcare technologies and therapies.Key Cardiac Stent Products:

• Resolute Onyx: Medtronic’s Resolute Onyx DES is known for its polymer coating that releases Zotarolimus, a drug that inhibits cell proliferation.
• Integrity Bare-Metal Stent (BMS): Medtronic also provides bare-metal stents for patients who may not benefit from DES.

Medtronic’s innovation in stent design has focused on enhancing deliverability and expanding the use of their DES for patients with complex lesions. They remain a market leader due to a broad product line addressing varying patient needs.

Boston Scientific Corporation

Boston Scientific Corporation (BSC), headquartered in Marlborough, Massachusetts and incorporated in Delaware,[2] is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. Boston Scientific is widely known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries.[3] With the full acquisition of Cameron Health in June 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (ICD) which they call the EMBLEM subcutaneous implantable defibrillator (S-ICD),Key Cardiac Stent Products:

• Promus Elite: Boston Scientific’s Promus Elite DES is built on their everolimus-eluting platform, featuring the company’s unique synergy of polymer and metal scaffold technology.
• SYNERGY: The SYNERGY stent is another leading drug-eluting stent, offering a bioabsorbable polymer coating.

Boston Scientific’s SYNERGY XD stent, featuring an ultra-thin strut and rapid polymer degradation, has gained attention in 2024 for improved healing and faster drug delivery.

B. Braun Melsungen AG

B. Braun is a German medical and pharmaceutical device company, which currently has more than 63,000 employees globally, and offices and production facilities in more than 60 countries. Its headquarters are located in Melsungen, in central Germany. The company was founded in 1839 and is still owned by the Braun family.^[2]

B. Braun has more than 5,000 different healthcare products, of which 95% are manufactured by the company. In 2018, the company had a revenue of 6.908 Billion Euros.

B. Braun, a German healthcare company, has a significant presence in the cardiac stent market through its Aesculap division, which focuses on high-quality surgical and interventional products.Key Cardiac Stent Products:

• Coroflex Blue Ultra: Known for its cobalt-chromium-based design, the Coroflex Blue Ultra is B. Braun’s leading DES, focusing on precision placement and patient safety.
• Coroflex ISAR: The ISAR series offers high flexibility, especially in treating small vessels.

B. Braun’s focus on improving DES for small-diameter vessels has given them an edge in treating complex coronary artery diseases. The Coroflex stent series continues to be highly regarded for its innovation and quality.

Biotronik

Biotronik (BIOTRONIK SE & Co. KG;[1][2] Biotronik Worldwide) is a limited partnership[1] multi-national cardiovascular biomedical research and technology company, headquartered in Berlin, Germany.

The company offers equipment for diagnosis, treatment, and therapy support in the areas of cardiac rhythm management, electrophysiology, and vascular intervention.[3] In the area of cardiac rhythm management, Biotronik Home Monitoring uses tele-monitoring technology to provide doctors with up-to-date information for implant patients.[4]

Biotronik employs more than 9,000 people worldwide in over 100 countries, with research and development activities in Europe, North America, and Singapore. It produces all critical components of its products in-house. One in every five employees at its Berlin headquarters works in research and development (R&D).Key Cardiac Stent Products:

• Orsiro: The Orsiro DES, known for its ultrathin struts and biodegradable polymer, is a significant player in the market, especially for complex procedures.
• Magmaris Bioresorbable Scaffold: A magnesium-based bioresorbable scaffold, Magmaris represents Biotronik’s advancement in fully biodegradable stent technologies.

Biotronik’s Orsiro Mission stent, an evolution of their successful Orsiro line, continues to be at the forefront in terms of deliverability, patient outcomes, and healing times.

Terumo Corporation

Terumo Corporation (テルモ株式会社, Terumo Kabushiki-gaisha) was founded in 1921 as Red Line Thermometer Corporation by a group of medical scientists led by Dr. Kitasato Shibasaburō to produce medical thermometers in Japan.

The company’s first product was “Jintan Taionkei”, the first Japanese-made thermometer available for sale, and it has since expanded into a medical devices manufacturer, producing medical disposables, cardiovascular systems and diabetes care products.[3][4]

In 1971, Terumo opened its first overseas office in the United States. Since then, the company has established subsidiaries in Europe (1971), South America, China, India, Philippines, Vietnam, Thailand and Australia. The company later expanded its product range to include coronary stents and catheters, and acquired, among others, the cardiovascular specialty companies Vascutek and Microvention in 2002 and 2006 respectively.Terumo Corporation, headquartered in Tokyo, Japan, is a global leader in medical technologies, including cardiovascular devices such as coronary stents. Terumo’s stent offerings are part of its comprehensive solutions for interventional cardiology.Key Cardiac Stent Products:

• Nobori DES: The Nobori stent releases Biolimus A9, an immunosuppressive drug, via a biodegradable polymer coating.
• Ultimaster: Terumo’s Ultimaster DES series is known for its unique hybrid coating technology.

In 2024, Terumo continues to expand its Ultimaster series, focusing on innovation in stent design for better precision and drug delivery, particularly in complex coronary anatomy.

Cook Medical

Cook Group Incorporated is an American privately held company based in Bloomington, Indiana, and primarily involved in manufacturing of medical devices. It was ranked #324 in Forbes’ 2008 America’s Largest Private Companies.[2] It has three main divisions: Cook Medical, Cook Services and Cook Properties. All three divisions are made up of several subsidiary companies.Cook Medical, headquartered in Bloomington, Indiana, USA, is a key player in developing innovative medical devices, including vascular stents. The company is known for its broad range of endovascular solutions.Key Cardiac Stent Products:

• Zilver PTX: This drug-eluting peripheral stent is one of Cook’s flagship products, focusing on peripheral artery disease treatment.
• Cook Formula Stents: Designed for coronary artery disease, Cook’s Formula series includes various DES and bare-metal stents.

While primarily focused on peripheral stenting technologies, Cook Medical has made significant inroads into coronary stents, especially in emerging markets, with its Formula stent series gaining traction globally.

MicroPort

MicroPort is a multinational medical technology developer and manufacturer that is primarily headquartered in Shanghai, China. It mainly designs and produces medical devices for a range of fields including cardiology, interventional radiology, orthopedics, electrophysiology, and surgical management.[2] MicroPort is considered one of the global Medtech Big 100 and has been consistently known as the leading spender in research and development by percentage of revenue.

The cerebrovascular diseases are characterized by high treatment risk and high fatality rate. With the development of interventional therapy and surgery, it is possible to have timely and effective treatment of most cerebrovascular diseases. However, it is still difficult for a number of patients suffering cerebrovascular diseases to obtain satisfactory treatment because of the particularity of their lesions and the restrictions of therapeutic materials. In 1996, a medical expert put forward the initial concept of treating patients suffering internal carotid artery defect with stent grafts. But it was difficult to realize the concept given that the challenges arising from the narrow and tortuous cerebrovascular lumens were beyond the domestic scientific and technological capacities at that time. Though the development of this new type of cerebrovascular stent graft has its special use, its application is limited and the market is small. Few companies in the world were willing to develop such products because of the high cost of research and development, long period and delicate manufacturing process. In 2004, MicroPort® officially organized a team to cooperate with the healthcare professional to develop the Cerebrovascular Stent Graft.

Biosensors International

Biosensors International Group, Ltd. is a medical device company that specializes in developing, manufacturing and licensing technologies for use in interventional cardiology procedures and critical care. The company was listed on the mainboard of the Singapore Exchange (SGX) in May 2005.

The global headquarters of the company are located in Singapore and hold the main manufacturing facilities and research and development centers. The European headquarters are in Morges, Switzerland. The Swiss office is also the legal manufacturer of BioMatrix, the company’s current leading product. Biosensors International also licenses its proprietary drug-eluting stent technologies to other medical device companies and specialty stent providers, including Terumo, Devax, Inc., and Xtent, Inc.

Biosensors International Group has a joint-venture in Hong Kong listed as Shandong Weigao to market and distribute coronary stents in China.

Meril Life Sciences

Founded in 2006, Meril is an India-based, global medical device company that is dedicated to the innovation, design and development of novel, clinically relevant and state-of-the-art devices. As a leading healthcare solutions company, our fundamental aim is to champion the alleviation of human suffering and improve quality of life. To enable this, we are committed to R&D, innovation in manufacturing medical technology, scientific communication, and contemporary distribution avenues.

Meril was established by the Bilakhia Group, to improve the quality of human life through innovative and advanced healthcare solutions. As a medical device manufacturer, we strive to improve the inventiveness in healthcare so that people’s lives are enriched. We continually seek excellence in providing answers to some of medicine’s toughest questions.

Meril manufactures medical solutions in the form of vascular intervention devices, orthopedic implants, robotics, endo-surgery, ENT products, and in-vitro diagnostics. It is our core commitment to ensuring the delivery of advanced healthcare solutions. Our inclination towards research and development is reflected in our diverse offerings. We ensure that we adhere to the best quality of standards in manufacturing, scientific communication and distribution to deliver path-breaking healthcare products to the world.

We collaborate with physicians and global innovators to identify unmet clinical needs and develop revolutionary therapies. We encourage research and academic collaborations and remain available to interact on exciting opportunities.

Headquartered in India with a manpower of more than 4000, Meril, by Bilakhia Group, currently conducts business in more than 100 countries. We have 100% subsidiaries in India, USA, Germany, Brazil, Russia, South Africa, Bangladesh and Turkey. We have set up operations in China and Japan too.

Alvimedica

Alvimedica is a manufacturer of medical devices, including coronary stents, balloon catheters, diagnostic and guiding catheters. The company was founded in 2007 by Turkish businessman İshak Alaton.[1]

Alvimedica’s headquarters are a 5,500 m² facility located at the free trade zone in Catalca, Istanbul, Turkey. Alvimedica has one of the biggest Class 10,000 cleanrooms in Europe.[2] With an area of 700 m², Alvimedica’s Good Manufacturing Practice-compliant facility contains the main assembly of catheter and stent systems.

Current projects include renal and cranial intravascular stents. These include Coracto, the first drug-eluting stent developed and manufactured in Turkey.[3] The company is also working on bio-degradable stents which completely dissolve in the vessel.

Medinol

Since its founding in 1992 by Dr. Judith Richter and Dr. Jacob (Kobi) Richter, Medinol has been at the forefront of pioneering new stent system technology.

Backed by over 400 patents, the company has delivered over 2,000,000 stents to date and its cutting-edge cardiovascular intervention technology continues to demonstrate extraordinary clinical results.

Medinol’s products constantly stretch the limits of innovation; the scientific spirit that led the company to pioneer the revolutionary NIR stent in 1996 still drives its multidisciplinary team today.

This breakthrough vastly expanded the patient base suitable for stenting and positioned stenting as the favored treatment over more risky, complex and expensive surgical intervention.

In-line with Medinol’s commitment to proven clinical excellence, NIR stents are some of the most clinically-studied Bare Metal Stents ever produced. Since 1995, NIR and its successors have been examined in over 25 clinical studies involving more than 5000 patients.

OrbusNeich

OrbusNeich Medical Group Holdings Limited (OrbusNeich) (/ˌɔːrbəsˈniːʃ/ or-bəs-NEESH) is a company that designs, develops, manufactures and markets medical devices for the treatment of vascular diseases.[1]

In 2013, OrbusNeich received CE mark for the world’s first and only dual therapy stent, the COMBO Dual Therapy Stent. The COMBO Stent features active endothelial progenitor cell (EPC) capture technology, which promotes the accelerated natural healing of the vessel wall after the implantation of a stent.[2] Several trials including a randomized study dedicated to patients with Acute Coronary Syndrome (ACS) and registries with a sizeable ACS patient subset demonstrated consistently low event rates and short DAPT option of 3 months, if needed.

Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. 

Our Code of Conduct aligns with our values and is our shared commitment to do what’s right for our people, our customers and their patients, our shareholders and our communities. Our Code is our compass—it empowers us to move forward the right way. By doing what’s right we earn trust, grow our business and achieve our mission.

At Stryker, quality is first in everything we do. We are driven to make healthcare better for our customers by providing innovative products and services that meet regulatory requirements through our effective quality system.

C. R. Bard, Inc.,

C. R. Bard, Inc., headquartered in Murray Hill, New Jersey, USA, was a developer, manufacturer, and marketer of medical technologies in the vascular medicine, urology, oncology, and surgical specialty fields. C. R. Bard marketed its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. An S&P 500 company with approximately 14,000 employees in 2015, Bard is perhaps best known for having introduced the Foley catheter in 1934.[citation needed]

In April 2017, C. R. Bard announced that it would be acquired by Becton, Dickinson and Company (BD).[4][self-published source] The transaction was completed later that year,[5] and the company became a wholly-owned subsidiary of BD, rebranded as Bard.

Integer

Integer® Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular and portable medical markets. The company provides innovative, high-quality technologies and manufacturing to Medical Device OEM’s to enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. Greatbatch Medical®, Lake Region Medical® and Electrochem® comprise the company’s brands.

Our story is one filled with 80 years of industry-changing innovations and exemplary manufacturing. It’s a legacy we are proud of as we continue to provide customers with unparalleled expertise, innovation and manufacturing excellence. We are guided by our values of Innovation, Collaboration, Inclusion, Candor, Integrity and Customer.

SLTL

Sahajanand Laser Technology Limited (SLTL),an organization founded in 1989, is responsible for bringing laser revolution in the World. Through inovation nitsfoundation,started maketing the medcral devices through Lancer Medial Techmology) a 109% subsidiary of LTL. With Technical ollboration &Patent Desientransfer withDr.Mate Neuss ofGermany , SLTLstarted indigenous manufacturing of Coronary products.

Since 2009.our gobalestablsment got even tronger when we received offer of alliance from an lrish company Lancers medical division is approved bystate and central licensing uthority and has been bult a per schedule M 3requirement of D&C ALt1940.Speaking fte facliythat brings componentsto lfe and spans in more than 10.0 Sq.F All th medical devices are being produced under lass 100 and lass 10 cdean room area. Lancerattains the flawlesslyfnished coronary stent andPTCA ballo catheter by tilin fierlaser built by the parent organization SLTL. The company has dedicated i.house R&D department approved by DSIR(Department of Scientific and lndustrial Research), acknowledged by DST (Department of science and Technology). ln orderto comply with lnternationalStandards of the product, medial dhvision invaried manufacturing and QC actitie intructons and corresponding standrds like MDD93/42/FEC,EN ISO 90012015,D&C Act 1940,EN IS013485.2016,GMP Guideline.ICH Guideline, GCP Guideline,ASTM standards and US FDA guidelines.

18.amg International GmbH

amg International GmbH develops, manufactures and sells on a world-wide basis stents, stent implantation systems and balloon catheters as well as auxiliary products such as guide wires and inflation devices, which are used primarily in the field of interventional cardiology. The company, which is headquartered 40km south east of Hamburg in Winsen (Luhe), Germany, was founded in December 1997. Over the years amg International GmbH became globally acknowledged for being specialized in manufacturing and marketing high quality products made of extraordinary innovative technology.

So, consequently according to amg’s vision and mission amg was World’s first enterprise having introduced to the market a coronary bare metal stent made of cobalt-chromium alloy, known as Arthos.

19.QualiMed

QualiMed was found in 1997 as an OEM manufacturer for implantable medical devices with a focus on the development and regulatory approval of coronary stents and their respective delivery devices. Later the business was expanded to peripheral vascular and non vascular implants. In the last years QualiMed started with the development of various biodegradable technologies, drug device combination products, and micro-intervention implants as part of its diversification and competitiveness strategy.

Up to date QualiMed has obtained CE approvals for more than 70 different products. QualiMed has developed over 4 Drug Eluting Stents of which it has two (2) CE approvals utilizing bio stable polymers and one more based on a proprietary fast absorbing biodegradable polymer coatings entering the commercialization phase.

Manufacturing is organized outside of Hamburg Germany in the town of Winsen where QualiMed runs two Class 10,000 Clean rooms according to EEC GMP standards. The company has production capabilities for stents, catheters, drug device combination products, and biodegradable technologies for a variety of interventional and surgical applications and holds more than 70 patents and utility models World Wide.

In 2008 Eric K. Mangiardi joined the Board of Directors at QualiMed as an active investor with a primary focus to assist the company in the development and implementation of its strategic plan, operational growth, and product diversification strategy.

20.SCITECH Medical

SCITECH Medical is a minimally invasive medical device company, founded over 20 years ago.

It started its activities in 2003, 7 years after the group already operates with import and distribution of medical devices, when it realized the potential of developing technology in the country in partnership with the Brazilian medical-scientific community.

Since its foundation, the company has filed several patent applications and has been recognized as an innovative company with 5 Finep awards, two of which are national.

With aspirations in the demanding global market, SCITECH has always invested a lot in the technical development of its products, in the production processes, in quality systems and in clinical research.

In 2004 Scitech launched its first nationally manufactured accessory. In the following year, it obtained the IS0 9001, ISO 13485 certifications.

In 2007, several products were launched that completed the cardiology and endovascular portfolio, including the coronary and vascular balloon catheter, the conventional CRONUS coronary stent and the SIOXX self-expanding vascular stent.

In 2012 Scitech obtained ANVISA approval to start marketing INSPIRON, a 3rd generation drug-eluting stent.

The following year, the migration to the company’s new technological center takes place. With a structure of more than 42,000m², with 7,000m² of built area, its production capacity becomes 5 times greater with the state of the art in the manufacture of medical devices and centralizing all the productive stages of stents, coronary and peripheral balloons.

The endovascular portfolio was complemented in 2016 with Embosoft microspheres for embolization and the Solaris self-expanding peripheral covered stent.

In the following years of 2017 and 2018 the company also started to operate in the Endosurgery and Endoscopy markets. In the endoscopy line, a wide portfolio of diagnostic products, ERCP, hemostasis, polypectomy and dilation are launched in addition to the line of Mitech endoscopic metal stents, previously distributed.

Thus, Scitech currently develops and manufactures a broad product portfolio for the Interventional Cardiology, Peripheral Vascular, Endosurgery and Endoscopy markets. The group has more than 280 direct employees, working in 5 countries: Brazil (commercial, manufacturing and logistics), Chile (commercial and logistics), Spain (commercial), Italy (commercial) and USA (logistics). In addition, it operates indirectly in more than 45 countries.

Currently the company develops and manufactures a wide portfolio of products for the Interventional Cardiology, Peripheral Vascular, Endosurgery and Endoscopy markets.

Conclusion

These are just a few highlights of the top 20 manufacturers, with others like Lepu Medical, Sahajanand Medical Technologies, and others contributing to the innovation in cardiac stent technologies. Each company is addressing key clinical challenges like patient safety, stent thrombosis, restenosis, and providing long-term benefits for those with coronary artery disease.

Micro Manufacturing For Medical Industries

---

We are manufacturer engaged in rapid prototyping for many years, is one the China’s largest manufacturers of 3D Printing,CNC machining and femtosecond laser cutting medical parts for surgical instruments and medical devices. With extraordinary technology and advanced equipment, we have become the leader of parts manufacturing for medical products. We provide customized medical prototyping process and various performance-critical medical component manufacturing services.

In order to meet the high-volume and high-precision development needs of medical equipment, high-speed, high-precision, intelligent, composite, and environmental protection have been the main development directions of our medical parts and micro manufacturing.Services including:

We always deliver high quality, precision Medical products on time and at affordable rates.